Located at the important tumor suppressor locus, 3p22, PLCD1 encodes an enzyme that mediates regulatory signaling of energy metabolism, calcium homeostasis and intracellular movements. We identified PLCD1 as a downregulated gene in aerodigestive carcinomas through expression profiling and epigenetic characterization. We found that PLCD1 was expressed in all normal adult tissues but low or silenced in 84% (16/19) gastric cancer cell lines, well correlated with its CpG island (CGI) methylation status. Methylation was further detected in 62% (61/98) gastric primary tumors, but none of normal gastric mucosa tissues. PLCD1 methylation was significantly correlated with tumor high stage. Detailed methylation analysis of 37 CpG sites at the PLCD1 CGI by bisulfite genomic sequencing confirmed its methylation. PLCD1 silencing could be reversed by pharmacological demethylation with 5-aza-2 0 -deoxycytidine, indicating a direct epigenetic silencing. Ectopic expression of PLCD1 in silenced gastric tumor cells dramatically inhibited their clonogenicity and migration, possibly through downregulating MMP7 expression and hampering the reorganization of cytoskeleton through cofilin inactivation by phosphorylation. Thus, epigenetic inactivation of PLCD1 is common and tumor-specific in gastric cancer, and PLCD1 acts as a functional tumor suppressor involved in gastric carcinogenesis.
Introduction
Gastric cancer is the second most frequent malignancy among all tumors worldwide (Parkin et al., 1993) , the leading cause of cancer mortality in many developing nations including China (Fuchs and Mayer, 1995) . The main cause of recurrence after curative resection of advanced tumors is peritoneal metastasis, which is also the most common reason for non-curative surgery (Maehara et al., 2000; Kaminishi, 2005) . Its molecular pathogenesis is believed to be a multi-step process involving the deregulation of multiple cancer genes including the inactivation of tumor suppressor genes (TSGs) (Panani, 2008) . 3p21-22 is an important chromosomal region, frequently deleted in multiple tumors including gastric cancer (Hesson et al., 2007) . It is believed that multiple candidate TSGs are located in this region. We have been searching for candidate TSGs at this locus in aerodigestive tumors through massive expression profiling and epigenetic characterization, and identified several interesting targets (Ying and Tao, manuscript in preparation) , including BLU and the two closely located 3p22.3 genes, DLEC1 (Qiu et al., 2008) and PLCD1. Recently, PLCD1 was also identified as a novel TSG in esophageal squamous cell carcinoma with its downregulation associated with loss of heterozygosity and promoter methylation, playing an important suppressive role in esophageal squamous cell carcinoma development and progression (Fu et al., 2007) .
Phospholipase C (PLC) is one of the key enzymes in the phosphoinositide metabolism system and hydrolyses phosphatidylinositol 4,5-bisphosphate (PI(4,5)P2) to generate two second messengers, inositol 1,4,5-trisphosphate and diacylglycerol. Diacylglycerol mediates the activation of protein kinase C and inositol 1,4,5-trisphosphate triggers the release of Ca 2 þ from intracellular stores. Phosphoinositide metabolism is an important intracellular signaling system involved in a variety of cellular functions, including secretion of hormones, transduction of neurotransmitters, growth factor signaling, membrane trafficking and regulation of the cytoskeleton (Janetopoulos and Devreotes, 2006; Santarius et al., 2006; Carvou et al., 2007) . To date, 13 PLC isozymes have been identified and categorized into six classes, b, g, d, e, z and Z-type, on the basis of structure and regulatory activation mechanisms (Rhee, 2001; Fukami, 2002; Nakahara et al., 2005) . Among the PLC family members, PLCD is considered to be the basic isoform and composed of three isozymes, PLCD1, D3 and D4 (Essen et al., 1996; Irino et al., 2004) .
In this study, we fully characterized the epigenetic alteration and functions of PLCD1 in gastric cancer. Our results showed that PLCD1 acts as a functional TSG in this tumor, and frequent methylation of PLCD1 is significantly correlated with the high-stage gastric cancer.
Results
Frequent downregulation and methylation of PLCD1 in gastric cancer cell lines First, we examined PLCD1 expression in a panel of human normal adult tissues by semi-quantitative RT-PCR. Our results showed that PLCD1 was expressed in all normal tissues including digestive tissues like stomach, though at different expression levels ( Figure 1a) .
We then determined PLCD1 expression in gastric cancer cell lines. Results indicated that PLCD1 expression was silenced or dramatically reduced in most cell lines (Figure 1b) . On the basis of the PLCD1 CpG island (CGI) sequence, we designed methylation-specific PCR (MSP) primers to analyse its methylation status. The PLCD1 CGI was methylated in all cell lines with silenced or reduced PLCD1 expression (Figure 1b) . Moreover, PLCD1 expression was significantly induced after Aza treatment in all cancer cell lines, representative results were shown in Figure 1b . We further examined the detailed methylation profiles of PLCD1 CGI by bisulfite genomic sequencing (BGS) analysis of 37 CpG sites, including those CpG sites analysed by MSP. Densely methylated CpG sites were detected in three cell lines with no PLCD1 expression (Figure 1c ). Meanwhile, both MSP and BGS showed that the PLCD1 CGI was dramatically demethylated after Aza treatment, showing a direct link between CGI methylation and PLCD1 silencing.
Correlation of PLCD1 methylation with clinicopathological features of gastric cancer patients We analysed PLCD1 methylation status in 98 primary gastric cancer cases. PLCD1 methylation was detected in 62% (61/98) of tumors, whereas none of the normal gastric mucosa tissues showed methylation. BGS analysis confirmed the MSP results in some cases (Figures 1c  and d ). PLCD1 methylation was found to be significantly correlated with high-stage tumors but not any other clinico-pathological parameter (Table 1) .
We further investigated PLCD1 expression in normal and gastric cancer tissues by immunohistochemistry. PLCD1 was highly expressed in the cytoplasm of epithelial and some stromal cells in the normal gastric mucosa (Figure 2 ). In contrast, PLCD1 expression was obviously decreased in primary gastric carcinomas. Of 60 tumor cases examined, 44 (73%) had no or weak expression compared with the normal gastric mucosa (Supplementary Table 2 ). We further studied whether there is any correlation between PLCD1 methylation status and its expression. Among 38 gastric carcinoma samples with PLCD1 methylation detected by MSP, only five (13%) showed PLCD1 expression, whereas 11/22 (50%) cases without methylation exhibited expression (P ¼ 0.005, Fisher's exact test) (Supplementary Table 2 ). 
PLCD1 suppressed the migration of gastric tumor cells
To evaluate the effect of PLCD1 expression on the migration of gastric tumor cells, wound-healing assay was performed. The PLCD1-transfected cells took much longer time (>48 h) to close a scratch wound than the control vector-transfected cells (Figure 3c ).
We further examined the migration of PLCD1-transfected cells by a 24-transwell system. As shown in Figure 3d , PLCD1 expression led to significant suppression of gastric tumor cell migration after a 24 h incubation.
Effect of PLCD1 on gastric tumor cell morphology and cytoskeleton The organization of the actin cytoskeleton was examined by rhodamine-conjugated phalloidin staining of F-actin. PLCD1-transfected cells had symmetrical round morphology with fewer thin fibers and formed nuclear F-actin rings, whereas the vector-transfected cells had asymmetrical polarized morphology and much thicker central stress fibers. Moreover, actin protrusion in the direction of movement was significantly reduced at the leading edge in PLCD1-transfected cells (Po0.05) (Figure 4a ). Effect of PLCD1 on the expression of MMP7 and cytoskeletal reorganization proteins To investigate the molecular mechanism of PLCD1 in suppressing the motility of gastric tumor cells, we examined the effect of PLCD1 on the expression and modification of a panel of MMPs and several key cytoskeletal reorganization regulators, including Cdc42, Rac1/2/3, active RhoA, phospho-Rac1/cdc42, cofilin and phospho-cofilin. We firstly checked intracellular MMPs levels by semi-quantitative RT-PCR, among them only MMP7 was apparently decreased in PLCD1-transfected cells. MMP7 also decreased at the protein level in PLCD1-transfected cells (Figure 4b ). Meanwhile, total cofilin decreased and phospho-cofilin increased in PLCD1-transfected cells. But unexpectedly, the RhoA activity was detected to be slightly elevated in PLCD1-transfected cells compared with that of vectortransfected cells. There was no difference of Cdc42, Rac1/2/3 and phospho-Rac1/cdc42 expression between the PLCD1-transfected and vector-transfected cells. (Figure 4c ).
PLCD1 inhibited peritoneal metastasis in mice
We did not observe any effect of PLCD1 by in vivo subcutaneous tumor model (data not shown). We then investigated whether PLCD1 transfection had a suppressive effect on peritoneal metastasis by in vivo model. All five mice inoculated with vector-transfected MKN-45 cells developed peritoneal metastasis with large volumes of bloody ascetic fluid (Figure 5a ). Among them, one died after 3 weeks (Table 2 ). Peritoneal 
Discussion
PLCD1 is an enzyme that mediates regulatory signaling of energy metabolism pathways, calcium homeostasis PLCD1 methylation in gastric cancer X-T Hu et al and intracellular movements (Ochocka and Pawelczyk, 2003) . Recently, it was characterized as a novel TSG for esophageal squamous cell carcinoma (Fu et al., 2007) . Our current study showed that PLCD1 is also frequently silenced by epigenetic alteration in a tumor-specific manner, and PLCD1 methylation is significantly correlated with high-stage gastric cancer. Moreover, PLCD1 functions as a TSG suppressing the clonogenicity and motility/migration/metastasis of gastric cancer. An early event of cell migration is characterized as the rapid reorganization of the actin cytoskeleton. Among the key factors controlling actin organization is PI(4,5)P2 of the plasma membrane. The effect of PI(4,5)P2 on actin dynamics is because of its interaction with a number of actin-binding proteins that govern all aspects of the actin skeleton architecture. Interestingly, a PLCD1-interacting protein, GTPase-activating protein, p122 (p122RhoGAP) isolated from rat, is localized in focal adhesion and may inhibit tumor cell migration through enhancing the PI(4,5)P2-hydrolyzing activity of PLCD1 (Homma and Emori, 1995; Sekimata et al., 1999; Kawai et al., 2004) . Later, deleted in liver cancer 1 (DLC1) gene, the human homolog of p122RhoGAP was identified as a TSG in several types of cancers through modulating cytoskeleton reorganization (Durkin et al., 2007) . This prompted us to study whether PLCD1 plays a tumor suppressive role in gastric cancer through inhibiting F-actin reorganization. Our results showed that PLCD1 is associated with an inhibitory effect on correct polarization, actin polymerization and stress fiber formation.
A common and early requirement for different forms of cell motility is actin polymerization, which drives the formation of cell protrusions that are used to adhere to the extracellular matrix, define the direction of migration and initiate cell crawling. Animal cells respond to signaling at the plasma membrane by remodeling their actin cytoskeleton (Ridley and Hall, 1992) . As the burst of actin polymerization in response to signaling is limited by the availability of actin monomers, a robust protrusive response also requires the coincident disassembly of the existing actin network. This is catalysed by the conserved actin-binding protein, cofilin (Carlier et al., 1997; Bamburg, 1999; Hotulainen et al., 2005) . It has been proposed that cofilin aids directional motility by severing actin filaments close to the cell front to create new barbed ends to promote new local actin polymerization (Mouneimne et al., 2004) . Multiple mechanisms have been identified that regulate cofilin, including cofilin inactivation through phosphorylation and polyphosphoinositide interaction, the effects of pH and the synergistic or competitive interactions of cofilin with other actin-binding proteins. It is also hypothesized that a pool of cofilin is associated with and inhibited by PIP2 (phosphatidylinositol 4,5-biphosphate), and that it can be released and activated on PLC-mediated PIP2 hydrolysis. Though it remains to be determined whether PIP2-mediated cofilin release occurs in gastric cells, our study indicated that cofilin phosphorylation was affected by changes of the PLCD1 expression level.
Activation of Rho GTPases has been shown to stimulate the formation of stress fibers and focal adhesions (Ridley and Hall, 1992 ). An unexpected finding in this work was that a slightly elevated RhoA activity was detected in PLCD1-transfected cells but not control cells with thicker central stress fibers. Although some RhoA activity is required for migration, highRhoA activity actually inhibits movement (Takaishi et al., 1994; Nobes and Hall, 1999) . RhoA activity could functionally antagonize the formation of protrusions through excessive contractility. Moreover, our results PLCD1 methylation in gastric cancer X-T Hu et al are consistent with earlier reports that RhoA may act upstream of PLCD1 pathway as PLCD1 expression did not affect RhoA activation significantly (Homma and Emori, 1995; Kawai et al., 2004) . On the other hand, the movement of cells into a tightly woven extracellular matrix may require an active proteolytic system, which can cleave a path for cell migration (Singer et al., 1999) . Among the extracellular matrixdegrading proteases, a great deal of attention has been paid to the MMP family. Though PLC activation was once indicated to be required for MMP13 protein expression, little is known about the possible role of PLCD1 in MMP7 protein expression. MMP7 is a matrixdegrading enzyme that is mainly produced from cancer cells, and involved in the invasion and metastasis of cancer. MMP7 was identified as the only differentially overexpressed gene in gastric carcinoma cells, in comparison to normal cells, among MMP family in a DNA microarray analysis (Mori et al., 2002) . Liu et al. (2002) reported that a high frequency of MMP7 protein at the invasive front in gastric cancer was related to poor prognosis. There are also several reports that peritoneal dissemination and lymph node metastasis are associated with MMP7 in gastric cancer (Honda et al., 1996; Nagashima et al., 1997; Adachi et al., 1998; Senota et al., 1998; Yonemura et al., 2000; Yonemura et al., 2001; Kitoh et al., 2004) . Thus, MMP7 is considered to have a direct role in the progression of gastric cancer. This study showed that MMP7 is a candidate gene directly or indirectly regulated by PLCD1 in gastric cancer.
In conclusion, our results showed that PLCD1 is frequently disrupted by epigenetic mechanism in gastric tumors in a tumor-specific manner. We also showed the PLCD1 could suppress the migration of gastric cancer cells, possibly through downregulating MMP7 expression and hampering the reorganization of cytoskeleton through cofilin inactivation by phosphorylation. A better understanding of the molecular functions of PLCD1 in tumor cell migration and cytoskeletal regulation would provide novel therapeutic strategies to block metastatic progression, reduce dissemination of tumor cells and improve cancer patient survival.
Materials and methods
Cell lines, tumor samples and normal control tissues A panel of gastric cancer cell lines (AGS, SGC-7901, KatoIII, MKN28, MKN45, BGC-823, NCI87, SNU1, SNU16, SNU719, YCC1, YCC2, YCC3, YCC6, YCC7, YCC9, YCC10, YCC11 and YCC16) were studied. A total of 98 patients with gastric cancer who underwent surgery from Feb 2004 to June 2006 at the Sir Run Run Shaw Hospital (Hangzhou, Zhejiang, China) were investigated in this study. There were 76 male and 22 female patients ranging in age from 24 to 79 years. The mean age of patients was 60.52±15.28 years. Patients who received preoperative chemotherapy were excluded from this study. Among these cases, 60 paraffin tumor blocks were available for immunohistochemistry. Eight normal gastric mucosa biopsy samples were used as normal controls. This study was approved and monitored by the ethics committee of the Sir Run Run Shaw Hospital, Zhejiang University.
5-aza-2
0 -deoxycytidine treatment Cells were seeded at a density of 1 Â 10 6 cells/ml. After overnight culture, cells were treated with Aza (Sigma-Aldrich, St Louis, MO, USA) at a final concentration of 10 mM for 3 days with changing of Aza-containing medium every 24 h, then harvested for DNA and RNA extraction.
Semi-quantitative RT-PCR
Semi-quantitative RT-PCR for the human multiple tissue panel, containing normal adult tissues (Stratagene, La Jolla, CA, USA or Millipore Chemicon, Billerica, MA, USA) was performed as described before (Ying et al., 2006) . The GAPDH mRNA sequence was also amplified as an internal control. Primers used in this study were listed in Supplementary Table 1 .
Bisulfite treatment and promoter methylation analysis Bisulfite modification of DNA, MSP and BGS were carried out as described earlier (Murray et al., 2004; Ying et al., 2006) . MSP and BGS primers were listed in Supplementary Table 1. PLCD1-expressing plasmid and cell transfection Gastric cancer cell lines, MKN-45 and SGC-7901 were transfected with control or PLCD1-expressing plasmid (Fu et al., 2007) , respectively, using FuGene 6 (Roche Molecular Systems, Alameda, CA, USA). Stable PLCD1-expressing clones (PLCD1-45 and PLCD1-7901) were selected for further study.
Colony formation assays
For colony formation assay by monolayer culture, cells (2 Â 10 5 / well) were plated in a 12-well plate and transfected with PLCD1-expression plasmid or the empty vector (2 mg each) using FuGene 6 (Roche, Indianapolis, IN, USA). Cells were collected and plated in a 10 cm dish 48 h post-transfection, and selected for 16-20 days with G418 (0.4 mg/ml). Surviving colonies (X50 cells/colony) were counted after Giemsa staining.
For the soft agar assay, B500 stable transfected cells were suspended in medium containing 0.3% low-melt agarose, seeded into a six-well plate that was overlaid with 0.5% lowmelt agarose, and allowed to grow for 2 weeks at 37 1C in 5% CO 2 . The colonies containing more than 50 cells were counted under a microscope. Three wells were analysed for each experiment.
Wound-healing assay Cell motility was assessed using a scratch wound assay. Stably transfected cells were cultured in 35 mm dishes until confluent. The cell layers were carefully wounded using sterile tips and washed twice with fresh medium. After incubation for 24 and 48 h, the cells were photographed under a phase contrast microscope. The experiments were performed in triplicate.
Cell migration assay Cells were trypsinized and resuspended in Dulbecco's modied Eagle's medium containing 1% fetal bovine serum at a density of 1 Â 10 6 cells/ml. 100 ml of the cell suspension was added into the upper chamber of a transwell (Corning, Corning, NY, USA) consisted of inserts containing 8-mm pore-size PET membrane. Dulbecco's modied Eagle's medium (600 ml) containing 10% fetal bovine serum was placed in the lower chamber. After a 24 h incubation at 37 1C, cells remained in the upper chamber was removed carefully by cotton swab and the membrane was cut off by an operating knife. The side facing lower chamber was stained with 0.05% crystal violet and attached cells were counted under a light microscope. The experiment was performed three times.
Cell proliferation assay
Stable clones were seeded in 96-well plates. The colorimetric MTT (Sigma-Aldrich) assay was used to measure cell numbers at various time points. The experiments were performed in triplicate.
Cell-cycle analysis A total of 1-2 Â 10 6 cells were cultured in Dulbecco's modied Eagle's medium containing 10% fetal bovine serum. Serum was withdrawn from culture medium when cells were 70% confluent. After 72 h, 10% fetal bovine serum was added in the medium for an additional 12 h. Cells were fixed in 70% ethanol, stained with propidium iodide and DNA content was analysed by FACSCalibur Flow Cytometer (BD Biosystems, Heidelberg, Germany).
Immunohistochemistry
The ChemMate EnVision Detection Kit (DAKO, Carpinteria, CA, USA) was used for immunohistochemistry according to company's recommended procedure. Briefly, after being deparaffinized and hydrated, the paraffin-embedded sections were placed in 0.01 M sodium citrate buffer (pH 6.0), and subjected to pressure cooker treatment for 2 min at full pressure with a domestic pressure cooker. After cooling to room temperature, the slides were rinsed with Tris buffered saline (0.05 M Tris/0.15 M NaCl, pH 7.6). The endogenous peroxidase activity was blocked by incubating the sections with 3% hydrogen peroxide. The primary antibody used in this study is a rabbit polyclonal antibody against the human PLCD1 protein (clone H-140, Santa Cruz Biotechnology, CA, USA). The sections were incubated with the primary antibody (1:400 dilution) overnight at 4 1C. Then, the ChemMate EnVision/HRP, Rabbit/Mouse (ENV) reagent was applied to the sections, followed by application of ChemMate DAB þ Chromogen included in the kit. The slides were lightly counterstained with hematoxylin.
Immunofluorescence Cells were cultured on glass coverslips and fixed in 3.7% paraformaldehyde in phosphate buffered saline (pH 7.4) for 10 min, permeabilized in 0.1% Triton X-100 in phosphate buffered saline for 4 min, blocked with 1% bovine serum albumin/phosphate buffered saline for 1 h, and then incubated at room temperature for 1 h with rhodamine-conjugated phalloidin (Invitrogen, Carlsbad, CA, USA) at 1:100 in blocking solution. Nuclei were counterstained with DAPI. Images were acquired with an Olympus BX51 microscope.
Western blot analysis
Western blot analysis was performed as described earlier (Ying et al., 2008) . Primary antibodies were used as follows: anti-Cdc42 rabbit monoclonal antibody; anti-Rac1/2/3 rabbit monoclonal antibody; anti-RhoA rabbit monoclonal antibody; anti-phospho-Rac1/cdc42 rabbit monoclonal antibody; anti-cofilin rabbit monoclonal antibody; anti-phosphocofilin rabbit monoclonal antibody (above antibodies were all from Cell Signaling, Beverly, MA, USA used at 1:1000); anti-MMP7 mouse monoclonal antibody (ThermoFisher Scientific, Fremont, CA, USA); anti-GAPDH mouse monoclonal antibody and anti-PLCD1 polyclonal antibody (1:1000, Santa Cruz Biotechnologies). Detection was carried out using the ECL kit (Pierce Chemical Co., Rockford, IL, USA) and the blots were developed using a Fujifilm Las-4000 Imaging System.
RhoA activation assay
To assess RhoA activation, the amount of RhoA-GTP bound to the Rhotekin RBD was determined using the Rho Activation Assay Kit (Upstate Biotechnology, Lake Placid, NY, USA) according to the instruction of the manufacturer.
In vivo subcutaneous tumor model All of the in vivo experimental protocols were approved by the animal care committee of Sir Run Run Shaw Hospital, Zhejiang University. Viable MKN-45 cells (2 Â 10 6 cells/ 0.2 ml/mouse) were injected subcutaneously into right and left flank of 5-week-old female BALB/c nude mice (eight mice per group). Tumor volume was assessed every 2 days for 4 weeks. Tumor volume was calculated by the following formula: (short diameter) 2 Â (long diameter)/2.
In vivo peritoneal metastasis model MKN-45 cells were injected into the peritoneal cavity of mice (2 Â 10 6 cells/1 ml/mouse, 5 mice per group). Four weeks later, all mice were killed. We determined the body weight, the number of tumor nodules, and the presence or absence of any bloody ascites as described before (Sako et al., 2004) .
Statistical analysis
The results are expressed as values of mean ± s.d. Statistical analysis was performed in SPSS 11.0 for Windows (SPSS Inc., Chicago, IL, USA). The two-tailed Chi-square and Fisher's exact tests were used to analyze the association of the PLCD1 CGI methylation with the different clinico-pathological parameters and the PLCD1 protein expression. For all tests, Po0.05 was considered to be of statistical significance.
